PDF(Pubmed)
Abstract：
To evaluate the randomized controlled trials (RCTs) of Curcumin and Curcuma longa Extract in the treatment of autoimmune diseases.
Databases such as Embase, Web of Science, PubMed and The Cochrane Library were searched from the database establishment to February 2022 to collect RCTs of Curcumin and Curcuma longa Extract in the treatment of autoimmune diseases. Then the literature was screened and the data were extracted. Meta-analysis was performed using RevMan 5.3 software.
A total of 34 records were included, involving 31 RCTs and 10 types of autoimmune disease. Among them, ankylosing spondylitis (AS) involves one RCT, Behcet \'s disease (BD) involves one RCT, Crohn \'s disease involves two RCTs, multiple sclerosis (MS) involves two RCTs, oral lichen planus involves six RCTs, psoriasis involves two RCTs, rheumatoid arthritis (RA) involves five RCTs, systemic lupus erythematosus (SLE) involves two RCTs, arteritis involves one RCT, ulcerative colitis (UC) involves nine RCTs. Among them, most of the RCTs of ulcerative colitis (UC), oral lichen planus, RA showed that curcumin and curcumin extracts improved clinical or laboratory results. Crohn \' s disease, MS, SLE, psoriasis included two RCTs; they all showed improvements (at least one RCT reported improvements in clinical outcomes). AS, BD and arteritis included only one RCT, and the clinical results showed improvement. However, due to the small number of RCTs and the small number of patients involved in each disease, there is still a need for more high-quality RCTs.
Curcumin and Curcuma longa Extract had good clinical efficacy in the treatment of Psoriasis, UC and RA, so Curcumin and Curcuma longa Extract could be used in the treatment of the above diseases in the future. The results of Meta-analysis showed that Curcumin and Curcuma longa Extract did not show efficacy in the treatment of oral lichen planus, while Takayasu arteritis, SLE, MS, AS, BD and CD did not report sufficient clinical data for meta-analysis. Therefore, large-sample, multi-center clinical trials are still needed for revision or validation.
Databases such as Embase, Web of Science, PubMed and The Cochrane Library were searched from the database establishment to February 2022 to collect RCTs of Curcumin and Curcuma longa Extract in the treatment of autoimmune diseases. Then the literature was screened and the data were extracted. Meta-analysis was performed using RevMan 5.3 software.
A total of 34 records were included, involving 31 RCTs and 10 types of autoimmune disease. Among them, ankylosing spondylitis (AS) involves one RCT, Behcet \'s disease (BD) involves one RCT, Crohn \'s disease involves two RCTs, multiple sclerosis (MS) involves two RCTs, oral lichen planus involves six RCTs, psoriasis involves two RCTs, rheumatoid arthritis (RA) involves five RCTs, systemic lupus erythematosus (SLE) involves two RCTs, arteritis involves one RCT, ulcerative colitis (UC) involves nine RCTs. Among them, most of the RCTs of ulcerative colitis (UC), oral lichen planus, RA showed that curcumin and curcumin extracts improved clinical or laboratory results. Crohn \' s disease, MS, SLE, psoriasis included two RCTs; they all showed improvements (at least one RCT reported improvements in clinical outcomes). AS, BD and arteritis included only one RCT, and the clinical results showed improvement. However, due to the small number of RCTs and the small number of patients involved in each disease, there is still a need for more high-quality RCTs.
Curcumin and Curcuma longa Extract had good clinical efficacy in the treatment of Psoriasis, UC and RA, so Curcumin and Curcuma longa Extract could be used in the treatment of the above diseases in the future. The results of Meta-analysis showed that Curcumin and Curcuma longa Extract did not show efficacy in the treatment of oral lichen planus, while Takayasu arteritis, SLE, MS, AS, BD and CD did not report sufficient clinical data for meta-analysis. Therefore, large-sample, multi-center clinical trials are still needed for revision or validation.
摘要：
评价姜黄素和姜黄提取物治疗自身免疫性疾病的随机对照试验。
数据库，如Embase，WebofScience,从数据库建立到2022年2月检索PubMed和Cochrane图书馆，收集姜黄素和姜黄提取物治疗自身免疫性疾病的随机对照试验。然后对文献进行筛选,提取数据。采用RevMan5.3软件进行Meta分析。
共包括34条记录，涉及31个RCT和10种自身免疫性疾病。其中,强直性脊柱炎（AS）涉及一个RCT，Behcet病（BD）涉及一次RCT，克罗恩病涉及两个随机对照试验,多发性硬化症（MS）涉及两个RCT，口腔扁平苔藓涉及六个RCT，牛皮癣涉及两个RCT，类风湿性关节炎（RA）涉及五个RCT，系统性红斑狼疮（SLE）涉及两个RCT，动脉炎涉及一个RCT，溃疡性结肠炎（UC）涉及9个RCT。其中,大多数溃疡性结肠炎（UC）的随机对照试验，口腔扁平苔藓,RA显示姜黄素和姜黄素提取物改善了临床或实验室结果。克罗恩病,MS,SLE,银屑病包括2个RCT;它们均显示改善(至少1个RCT报告临床结局改善).AS,BD和动脉炎仅包括一个RCT，临床结果显示改善。然而,由于RCT数量少，每种疾病涉及的患者数量少，仍然需要更多高质量的RCT。
姜黄素和姜黄提取物治疗银屑病有良好的临床疗效，UC和RA,因此姜黄素和姜黄提取物可用于上述疾病的治疗。Meta分析结果显示姜黄素和姜黄提取物治疗口腔扁平苔藓疗效不明显,而大动脉炎，SLE,MS,AS,BD和CD没有报告足够的临床数据进行荟萃分析。因此,大样本,仍需要多中心临床试验进行修订或验证.
数据库，如Embase，WebofScience,从数据库建立到2022年2月检索PubMed和Cochrane图书馆，收集姜黄素和姜黄提取物治疗自身免疫性疾病的随机对照试验。然后对文献进行筛选,提取数据。采用RevMan5.3软件进行Meta分析。
共包括34条记录，涉及31个RCT和10种自身免疫性疾病。其中,强直性脊柱炎（AS）涉及一个RCT，Behcet病（BD）涉及一次RCT，克罗恩病涉及两个随机对照试验,多发性硬化症（MS）涉及两个RCT，口腔扁平苔藓涉及六个RCT，牛皮癣涉及两个RCT，类风湿性关节炎（RA）涉及五个RCT，系统性红斑狼疮（SLE）涉及两个RCT，动脉炎涉及一个RCT，溃疡性结肠炎（UC）涉及9个RCT。其中,大多数溃疡性结肠炎（UC）的随机对照试验，口腔扁平苔藓,RA显示姜黄素和姜黄素提取物改善了临床或实验室结果。克罗恩病,MS,SLE,银屑病包括2个RCT;它们均显示改善(至少1个RCT报告临床结局改善).AS,BD和动脉炎仅包括一个RCT，临床结果显示改善。然而,由于RCT数量少，每种疾病涉及的患者数量少，仍然需要更多高质量的RCT。
姜黄素和姜黄提取物治疗银屑病有良好的临床疗效，UC和RA,因此姜黄素和姜黄提取物可用于上述疾病的治疗。Meta分析结果显示姜黄素和姜黄提取物治疗口腔扁平苔藓疗效不明显,而大动脉炎，SLE,MS,AS,BD和CD没有报告足够的临床数据进行荟萃分析。因此,大样本,仍需要多中心临床试验进行修订或验证.
